Pharmaceutical company Enesi Pharma, a developer of unique injectable solid dose vaccine products, revealed on Monday that it has appointed internationally recognised vaccine and infectious disease expert Dr Steven Chatfield to its Scientific Advisory Board (SAB).
The company said Dr Chatfield has nearly 40 years' experience in R&D, executive, board and advisory roles across several of public and private healthcare organisations focused on vaccines and infectious diseases.
Currently, Dr Chatfield is a non-executive director of the Vaccines Manufacturing & Innovation Centre (VMIC), a new purpose-built, state-of-the-art facility in Oxford, UK. This new centre enables academic and industry collaboration on the development, design and manufacture of vaccines.
Dr Chatfield is also a Director of the UK Cell and Gene Therapy Catapult and a member of the Scientific Advisory Board of the Jenner Institute at the University of Oxford, as well as chairman of Prokarium Ltd, a UK company that develops oral vaccine products for infectious diseases and cancer.
Earlier, Dr Chatfield was chief scientific officer and executive vice president of global vaccine business Strategic Investments for Emergent BioSolutions and was also president and CEO of its UK operation. Additionally, he was a director of Vaccitech, a private UK vaccine specialist and a director of the Centre for Emergency Preparedness and Response at the UK Health Protection Agency (now Public Health England).
In addition, Dr Chatfield has published over 100 publications on the molecular basis of pathogenicity of bacterial and viral infections and work directed towards the development of novel vaccines and immunotherapeutics, being a named inventor on 20 patents.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma